Accendra Health names Gardner-Smith CEO: what it means for OMI stock
Published on 10/02/2026 at 03:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
OMI stock (ISIN US6907321029) enters a leadership transition after Accendra Health named Kenneth Gardner-Smith as its next chief executive officer on September 17, 2026, effective early in the fourth quarter of 2026, according to finanzen.at. The issuer formerly known as Owens & Minor is now building its investment case around home-based healthcare and a new management team.
Leadership changes the investment case
Gardner-Smith will succeed Edward A. Pesicka, who announced his retirement in August, with the handover scheduled for early in the fourth quarter of 2026. finanzen.at reported that Gardner-Smith has served on the board since March 2022 and previously led Veritas Veterinary Partners.
The company change is more than a personnel event. MarketScreener identifies Accendra Health as formerly Owens & Minor and lists the security on the NYSE under ACH, while the ISIN remains US6907321029.
Second-quarter figures show pressure
In the second quarter of 2026, like-for-like revenue grew 2.00 percent, while sleep revenue increased 5.50 percent year over year, according to Fortune. Adjusted EBITDA exceeded USD 60 million, and adjusted EBITDA less patient service equipment capital expenditure was USD 16.30 million.
The comparison is mixed. Diabetes growth improved by 4.00 percentage points from the first quarter, but the company said collection issues reduced revenue and adjusted EBITDA by USD 20 million in the first half of 2026. That quantified drag helps explain why management is emphasizing execution and cost control.
Debt and outlook set the next test
Accendra Health reported total debt of USD 1.72 billion after its June balance-sheet optimization, more than USD 55 million below the March level, according to Fortune. The company expects full-year 2026 revenue of USD 2.45 billion-USD 2.55 billion and adjusted EBITDA of USD 300 million-USD 320 million.
Free cash flow is expected to be break even to slightly positive for full-year 2026. For investors, the central question is whether the new CEO can convert the planned cost reductions, payer agreements and sleep-business initiatives into stronger cash generation while the debt load remains substantial.
Company details
Accendra Health at a glance
- Company: Accendra Health, Inc.
- ISIN: US6907321029
- WKN: 904611
- Ticker: ACH
- Primary exchange: NYSE
- Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
- Second-quarter revenue growth: 2.00 percent like-for-like in the second quarter of 2026
- Full-year 2026 revenue outlook: USD 2.45 billion-USD 2.55 billion
